Events

'Go Healthy with Taiwan' invites submissions from Australian health innovators June 17, 2025

The global initiative aims to engage governments, institutions, enterprises, and organisations in submitting innovative proposals that integrate Taiwan’s home-grown health innovations.

Recce Pharmaceuticals announces non-dilutive financing via facility with Avenue Capital Group June 17, 2025

James Graham, CEO of Recce Pharmaceuticals, said, “This facility marks a significant step in strengthening our capital position at a critical juncture."

Clarity enters manufacturing agreement for Cu-64 SAR-bisPSMA with SpectronRx June 17, 2025

Clinical-stage radiopharmaceutical company Clarity Pharmaceuticals (ASX:CU6) has entered into a commercial manufacturing agreement with SpectronRx for the company's lead diagnostic product, 64Cu-SAR-bisPSMA.

New pathway for mRNA drug delivery shows shape of things to come June 17, 2025

Scientists working at RMIT University and Osaka University have discovered that the internal shape of tiny drug-delivery particles, known as lipid nanoparticles, has a significant impact on how well our cells absorb them.

Amplia says pathological complete response in patient from ACCENT trial June 17, 2025

Amplia Therapeutics (ASX:ATX) has announced important new data from its ongoing ACCENT clinical trial in pancreatic cancer.

Australian company secures FDA approval to progress development of CAR-T therapy June 17, 2025

The US FDA has approved an Investigational New Drug, enabling the Melbourne-based company Myrio to progress its lead product into human clinical trials.

Radium Capital unleashes $400m war chest for Australian innovators June 12, 2025

Radium Capital, Australia’s leader in R&D finance, has announced plans to lend $400 million to Australian innovators over the next 12 months.

Island reports successful Phase 2 clinical trial of ISLA-101 in dengue model June 12, 2025

Australian antiviral drug development company, Island Pharmaceuticals (ASX:ILA) has provided top-line results from its Phase 2a/b PROTECT Trial of ISLA101 in a human challenge model of dengue virus infection.

Cochlear lauunches the world’s first smart hearing implant system June 12, 2025

Cochlear has launched its new smart cochlear implant system, Cochlear Nucleus Nexa System, which is designed and manufactured in Australia.

Cyclopharm secures maximum US patent extension for Technegas to 2031 June 11, 2025

Cyclopharm (ASX:CYC) has announced that the United States Patent and Trademark Office (USPTO) has granted the maximum allowable patent term extension of five years covering the TECHNEGAS Kit (technetium Tc-99m labelled carbon) to 2031.

Registrations now open for Australia’s biggest week in biotech June 11, 2025

AusBiotech 2025, Australia’s premier life sciences and investment conference, has officially opened early bird registrations, and the countdown is on.

Strengthening sovereign capability through 'Made in Australia’ medtech manufacturing June 10, 2025

In its once-in-a-decade report ‘Our Future World’, Australia’s national science agency identified seven global megatrends that will shape our lives in the coming decades. Among them is the escalating health imperative.

Most Read

Recce Pharmaceuticals announces non-dilutive financing via facility with Avenue Capital Group

Australian company secures FDA approval to progress development of CAR-T therapy

New pathway for mRNA drug delivery shows shape of things to come

'Go Healthy with Taiwan' invites submissions from Australian health innovators

Clarity enters manufacturing agreement for Cu-64 SAR-bisPSMA with SpectronRx

New Stories

'Go Healthy with Taiwan' invites submissions from Australian health innovators

Recce Pharmaceuticals announces non-dilutive financing via facility with Avenue Capital Group

Clarity enters manufacturing agreement for Cu-64 SAR-bisPSMA with SpectronRx

New pathway for mRNA drug delivery shows shape of things to come

Amplia says pathological complete response in patient from ACCENT trial

Australian company secures FDA approval to progress development of CAR-T therapy

Radium Capital unleashes $400m war chest for Australian innovators

Sign In

Most Read

Recce Pharmaceuticals announces non-dilutive financing via facility with Avenue Capital Group

Australian company secures FDA approval to progress development of CAR-T therapy

New pathway for mRNA drug delivery shows shape of things to come

'Go Healthy with Taiwan' invites submissions from Australian health innovators

Clarity enters manufacturing agreement for Cu-64 SAR-bisPSMA with SpectronRx

Follow Us

New Stories

'Go Healthy with Taiwan' invites submissions from Australian health innovators

Recce Pharmaceuticals announces non-dilutive financing via facility with Avenue Capital Group

Clarity enters manufacturing agreement for Cu-64 SAR-bisPSMA with SpectronRx

New pathway for mRNA drug delivery shows shape of things to come

Amplia says pathological complete response in patient from ACCENT trial

Australian company secures FDA approval to progress development of CAR-T therapy

Radium Capital unleashes $400m war chest for Australian innovators